Lyfgenia (lovotibeglogene autotemcel) / Genetix Biotherapeutics - LARVOL DELTA

Sickle Cell Disease: From Ancient Origins to Modern Breakthroughs in Gene Therapy. (PubMed, Biomedicines) - "Current management rests on supportive pharmacological interventions, including hydroxyurea, chronic transfusion therapy, L-glutamine, and multimodal pain management, complemented by lifestyle modifications. Curative approaches have advanced substantially: hematopoietic stem cell transplantation (HSCT) remains the established standard of cure, while the regulatory approvals in late 2023 of the CRISPR/Cas9-based exagamglogene autotemcel (Casgevy) and the lentiviral vector-based lovotibeglogene autotemcel (Lyfgenia) represent the most transformative development in the history of SCD therapeutics. This review traces the disease from its ancient origins and molecular characterization through to its clinical manifestations, inheritance patterns, screening strategies, and the full spectrum of current and emerging therapies. Persistent challenges, prohibitive treatment costs, healthcare inequities, the ethical dimensions of genome editing, and the urgent need for long-term..."

Journal • Review • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Infectious Disease • Inflammation • Malaria • Pain • Rare Diseases • Sickle Cell Disease • Transplantation • HBB

Supportive care, prevention, and emerging therapies for acute chest syndrome in sickle cell disease. (PubMed, Expert Rev Hematol) - "This review synthesizes data on supportive measures (fluid management, analgesia, antibiotics, oxygen/respiratory support, and transfusion), preventive interventions (incentive spirometry and nocturnal bilevel positive airway pressure), disease-modifying therapies (hydroxyurea, L-glutamine), investigational agents (therapeutic anticoagulation, inhaled nitric oxide, and pyruvate kinase activators), and recently approved gene therapies (exagamglogene autotemcel, lovotibeglogene autotemcel)...Gene therapies represent a paradigm shift toward durable or potentially curative prevention of ACS. With expanding access to these therapies, ACS may become a rare complication of SCD, although significant barriers related to cost, infrastructure, and global equity must be overcome."

Journal • Gene Therapies • Genetic Disorders • Hematological Disorders • Pain • Preventive care • Sickle Cell Disease

Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials. (PubMed, Eur J Haematol) - "Autologous gene therapy for SCD produces substantial short- to medium-term reductions in severe VOEs and improves hemoglobin biology, but certainty remains limited by single-arm designs, small samples, evolving protocols, and incomplete long-term follow-up. Successful delivery depends on separable processes: transfusion preparation, mobilization, apheresis collection, ex vivo manufacturing/editing, product release, conditioning, and reinfusion. Long-term safety, fertility, organ outcomes, reimbursement, and global scalability remain unresolved implementation barriers."

Journal • Review • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical Care. (PubMed, Cells) - "The approval of two autologous gene therapy products in 2023, exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel), marked a turning point for the SCD population and the gene therapy field in general. Critical research priorities include long-term safety surveillance, comparative effectiveness studies, pediatric trials below 12 years, and validated patient-reported outcome instruments. Base editing, non-genotoxic conditioning, and in vivo delivery represent the most promising avenues to broaden access and reduce treatment burden."

Journal • Review • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Pediatrics • Sickle Cell Disease • Transplantation

Cell & Gene Therapy Clinical Trial Trends (2021–2025) and Strategic Outlook (2026–2028): Mechanism Shifts and Regulatory Drivers (ASGCT 2026) - "Key milestones include the first CRISPR-based approval (Casgevy™), lentiviral therapy (Lyfgenia™), and AAV gene therapy (Elevidys™). Europe recorded $0.4B, with investment dominated by public-market activity and supported by strategic alliances, while Asia-Pacific generated $0.2B, led mainly by early-stage venture financing. Together, these patterns highlight a capital landscape in which North America continues to anchor CGT funding, Europe maintains steady public-equity engagement, and Asia-Pacific expands through venture-driven growth, underscoring the need for region-specific strategies to support CGT development and commercialization."

Clinical • First-in-human • Gene therapy • Gaucher Disease • Gene Therapies • Immunology • Metabolic Disorders • Ophthalmology • Pompe Disease • Retinal Disorders • Solid Tumor • FOXG1

A qualitative study understanding SCD-focused hematologists' decision making around gene therapy referrals (ASGCT 2026) - "Introduction Exagamglogene autotemcel (i.e., Casgevy) and Lovotibeglogene autotemcel (i.e., Lyfgenia) are estimated to cost $2-3 million per patient with sickle cell disease (SCD)...Factors perceived by hematologists to be important to patients when deciding to pursue gene therapy included social support, healthcare fatigue, infertility risk, conditioning/plerixafor side effects, and access to opioids if functionally cured...It is critical that we begin to understand how hematologists (i.e., especially those providing care at SCD centers of excellence) and patients are thinking about gene therapy allocation. A timely understanding of drivers and deterrents to gene therapy referrals will allow for proactive equity interventions."

Gene therapy • Gene Therapies • Hematological Disorders • Infertility • Sexual Disorders • Sickle Cell Disease

A RT-qPCR assay for precise detection and absolute quantification of the T87Q β-globin variant in erythroid progeny of lentivirus transduced human CD34+ cells (ASGCT 2026) - "Despite the FDA approval of β-globin gene therapies, Lyfgenia and Zynteglo, a reliable companion diagnostic for the vector-encoded gene product is lacking. Conclusion This assay provides a precise, sensitive, and quantitative method to measure βT87Q globin expression in erythoid progeny of LVV transduced CD34+ hematopoietic stem cells. By integrating these results with hematological metrics, like total hemoglobin, this companion diagnostic assay could define the expression thresholds necessary for treatment efficacy, and has the potential to become a simple prognostic benchmark for monitoring patient outcomes in T87Q β-globin gene therapies."

Gene Therapies • Hematological Malignancies • Leukemia • CD34 • RPL13A

VARIATION IN CASGEVY AND LYFGENIA COVERAGE CRITERIA ACROSS STATE MEDICAID PLANS (ISPOR 2026) - "Two policies imposed an age restriction, excluding patients older than 50 years and seven imposed step therapy requirements, requiring failure of hydroxyurea before gaining access. Access to Casgevy and Lyfgenia varies across states not enrolled in the CGT Access Model. In the absence of centralized decision-making, coverage policies are inconsistent, resulting in differing access barriers for the same therapies. Greater standardization of access criteria may help reduce geographic disparities for patients with sickle cell disease."

Medicaid • Reimbursement • US reimbursement • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

BUDGET IMPACT ANALYSIS OF EXAGAMGLOGENE AUTOTEMCEL FOR PATIENTS WITH SICKLE CELL DISEASE AND RECURRENT VASO-OCCLUSIVE EVENTS IN THE UNITED STATES (ISPOR 2026) - "Exagamglogene autotemcel was associated with lower modeled per-patient total treatment cost than lovotibeglogene autotemcel, primarily due to lower drug acquisition cost. Administration and grade 3-4 adverse event costs were higher for exagamglogene autotemcel."

Clinical • HEOR • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Characterizing Acute Pain Occurrences After Gene Therapy With Lovotibeglogene Autotemcel for SCD (ASPHO 2026) - "Most individuals treated with lovo-cel or allo-HSCT became VOE-free, but a minority experienced acute pain not aligned with traditional mechanisms of VOE. These findings support improved classification, anticipatory counseling, and individualized pain management for patients pursuing transformative therapies. These studies were funded by Genetix Biotherapeutics."

Gene therapy • Addiction (Opioid and Alcohol) • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pain • Sickle Cell Disease

REFRAMING PAIN AND VOES AFTER TRANSFORMATIVE THERAPIES FOR SICKLE CELL DISEASE: INSIGHTS FROM GENE THERAPY WITH LOVOTIBEGLOGENE AUTOTEMCEL (EBMT 2026) - P, P1/2, P3 | "Most individuals treated with lovo-cel or allo-HSCT became VOE-free; however, a minority continued to experience acute pain not consistent with traditional VOE. People with acute pain post-treatment need recognition, validation, and counseling; with a focus on long-term management. Improved classification frameworks are needed to optimize long-term approaches to pain management."

Gene therapy • Addiction (Opioid and Alcohol) • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Inflammation • Pain • Sickle Cell Disease

BRIDGING READINESS AND REALITY: U.S. PEDIATRIC HEMATOLOGISTS' PERSPECTIVES ON GENE THERAPY FOR SICKLE CELL DISEASE IN THE POST-APPROVAL ERA (EBMT 2026) - "Confidence was lowest regarding long-term risks (busulfan toxicity, clonal hematopoiesis, secondary malignancies) and mechanistic differences between Casgevy and Lyfgenia.Insurance approval emerged as the most cited determinant of whether a patient would be referred (72%), ahead of disease severity, caregiver readiness, or institutional infrastructure. U.S. pediatric hematologists are enthusiastic about GT for SCD, but implementation is constrained by inconsistent referral practices, limited product-specific knowledge, and payer-driven access barriers. As GT expands globally, these findings offer both contrast and guidance for European systems. While Europe's nationalized health models may mitigate some structural hurdles, the variability in provider knowledge, absence of unified SDM protocols, and need for long-term safety data are universal concerns."

Clinical • Gene therapy • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Pediatrics • Sickle Cell Disease

BRIDGING READINESS AND REALITY: U.S. PEDIATRIC HEMATOLOGISTS' PERSPECTIVES ON GENE THERAPY FOR SICKLE CELL DISEASE IN THE POST-APPROVAL ERA (EBMT 2026) - "Confidence was lowest regarding long-term risks (busulfan toxicity, clonal hematopoiesis, secondary malignancies) and mechanistic differences between Casgevy and Lyfgenia.Insurance approval emerged as the most cited determinant of whether a patient would be referred (72%), ahead of disease severity, caregiver readiness, or institutional infrastructure. U.S. pediatric hematologists are enthusiastic about GT for SCD, but implementation is constrained by inconsistent referral practices, limited product-specific knowledge, and payer-driven access barriers. As GT expands globally, these findings offer both contrast and guidance for European systems. While Europe's nationalized health models may mitigate some structural hurdles, the variability in provider knowledge, absence of unified SDM protocols, and need for long-term safety data are universal concerns."

Clinical • Gene therapy • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Pediatrics • Sickle Cell Disease

REFRAMING PAIN AND VOES AFTER TRANSFORMATIVE THERAPIES FOR SICKLE CELL DISEASE: INSIGHTS FROM GENE THERAPY WITH LOVOTIBEGLOGENE AUTOTEMCEL (EBMT 2026) - P, P1/2, P3 | "Most individuals treated with lovo-cel or allo-HSCT became VOE-free; however, a minority continued to experience acute pain not consistent with traditional VOE. People with acute pain post-treatment need recognition, validation, and counseling; with a focus on long-term management. Improved classification frameworks are needed to optimize long-term approaches to pain management."

Gene therapy • Addiction (Opioid and Alcohol) • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Inflammation • Pain • Sickle Cell Disease

Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders. (PubMed, J Blood Med) - "In this review, we discuss each of the six therapies that now have regulatory approval for treatment in the United States: Roctavian (valoctocogene roxaparvovec) for hemophilia A, Beqvez (fidanacogene elaparvovec) and Hemgenix (etranacogene dezaparvovec) for hemophilia B, Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease, Zynteglo (betibeglogene autotemcel) for β-thalassemia, and Casgevy (exagamglogene autotemcel) for either sickle cell disease or β-thalassemia. Overall, results are very encouraging, often freeing patients from the need for coagulation factor or red blood cell (RBC) infusions, albeit that for some of these diseases there is room for further improvement in terms of safety and therapeutic durability, which may be achieved with next-generation gene therapy products. However, improvements are needed to address issues with durability of results, side effects, and accessibility of these therapies."

Journal • Review • Beta-Thalassemia • Gene Therapies • Genetic Disorders • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases • Sickle Cell Disease

Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda's context. (PubMed, Gene Ther) - "Using a three-state Markov model to estimate lifetime costs of standard-of-care in Uganda, two U.S.-based CEA models were adapted using scaling factors and applied to two authorized gene therapies for SCD, Lyfgenia™ (lovo-cel) and Casgevy® (exa-cel), assuming biologically consistent efficacy across populations. This study demonstrates that Casgevy could be cost-effective in Uganda at a scaled cost when societal benefits are considered. This framework enables CEAs for emerging therapies where local clinical trial data are limited, supporting local decision-makers, global funders, and manufacturers in advancing equitable access to transformative therapies in LMICs."

HEOR • Journal • Gene Therapies • Genetic Disorders • Hematological Disorders • Rare Diseases • Sickle Cell Disease

Orsini Now Distributing Gene Therapies LYFGENIA, ZYNTEGLO, SKYSONA (PRNewswire)

Commercial • Beta-Thalassemia • CNS Disorders • Genetic Disorders • Sickle Cell Disease

Challenges in molecular test interpretation in patients with prior gene therapy for beta-thalassemia and sickle cell disease: one laboratory's experience (ACMG 2026) - "Similarly, for Case 2, the clinician confirmed this individual received lovo-cel gene therapy for SCD...Post-therapy monitoring should be based on parameters outlined in manufacturer materials and regulatory guidance. Laboratories should be aware of this rare but complex testing scenario so it can be handled appropriately."

Clinical • Gene therapy • Beta-Thalassemia • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • HBB

Venous Thromboembolism in Recipients of Ex-Vivo Gene Therapy for Adolescent, Young Adult Patients with Sickle Cell Disease (TCT-ASTCT-CIBMTR 2026) - "3 out of 5 recipients undergoing Lovotibeglogene autotemcel gene therapy developed VTE at various time points of their gene therapy journey before infusion of the gene modified cells... This report demonstrates potential benefit for instituting prophylactic anticoagulation in patients undergoing ex-vivo gene therapy for SCD. Given the baseline hypercoagulable state of SCD patients, this case series demonstrates that the added risk of central line placement may warrant consideration of prophylactic anticoagulation and proposal of an algorithm including anti-coagulant medication selection for decision making in these patients. 1."

Gene therapy • Preclinical • Cardiovascular • Gene Therapies • Genetic Disorders • Hematological Disorders • Infectious Disease • Respiratory Diseases • Sickle Cell Disease • Venous Thromboembolism • CD34 • SCD

A Population Health-Based Approach to Inform the Provisioning of Gene Therapies for Severe Sickle Anemia in a Large, Vertically Integrated, Value-Based Health Care System. (TCT-ASTCT-CIBMTR 2026) - "Objectives: We describe a population based approach to the identification and care navigation of severe sickle cell patients in collaboration with contracted centers of excellence to provision access to gene therapies (Lyfgenia & Casgevy). Providing access to gene therapy for severe sickle cell patients in a vertically integrated health system requires a data informed, multidisciplinary team. Future refinement of our workflow will be to include patient care experience feedback and to focus on patients aged 12-18yrs who may reap the benefits of gene theapy earlier and decrease the expected marked increase in complications and health care cost as they become adolescent/young adults. 1 ."

Clinical • Gene therapy • Anemia • Autoimmune Hepatitis • Gene Therapies • Hematological Disorders • Hepatology • Immunology • Infertility • Inflammation • Sexual Disorders • Sickle Cell Disease

Outcomes of Gene Therapy and Allogeneic Hematopoietic Cell Transplantation for Sickle Cell Disease: A Single-Center Retrospective Analysis (TCT-ASTCT-CIBMTR 2026) - "14 pts with sickle cell anemia (SCA) underwent 15 cellular therapies at our center, including 7 GT (lovo-cel via HGB-206/210 trials) and 8 alloHCT (3 haploidentical donors (haplo) and 5 matched-related donor (MRD))...Graft failure occurred in 2 alloHCT compared to 0 in GT, both in pts who received non-myeloablative conditioning (alemtuzumab/total body irradiation) for MRD alloHCT with 1 patient then proceeding to a second MRD alloHCT...Gene therapy and allogeneic cell transplantation offer durable engraftment and hemoglobin S suppression in sickle cell anemia. Survival, hospital length-of-stay, and infectious complications were similar between treatment groups in our study."

Gene therapy • Retrospective data • Addiction (Opioid and Alcohol) • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Neutropenia • Retinal Disorders • Septic Shock • Sickle Cell Disease • Transplantation

Accelerating Access to Gene Therapy: Lessons from Commercial Implementation in Sickle Cell Disease and Transfusion-Dependent Thalassemia (TCT-ASTCT-CIBMTR 2026) - "With >700 patient-years of follow-up, beti-cel (Zynteglo; US approval Aug-2022) and lovo-cel (Lyfgenia; US approval Dec-2023) are now in routine use. This real-world analysis is the first to show that national-scale delivery of commercial gene therapy is feasible within a coordinated ecosystem. Coverage policies indicate broad access across public and private payers. These findings offer a functioning model for gene therapy implementation."

Gene therapy • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. (PubMed, Mol Ther Nucleic Acids) - "Since then, the US FDA has approved nearly 30 new viral gene therapy programs, with notable examples including Zolgensma, Spinraza, Hemgenix, Zynteglo, Lyfgenia, Kymriah, Skysona, and Tecelra...In this review, we examine the range of these therapeutics and their viral carriers, focusing primarily on LVs and AAVs. We provide a snapshot of the current status of the field and highlight some of the current challenges in the clinical application of gene therapy, with particular emphasis on viral CRISPR-Cas-based technologies and their future potential."

Journal • Review • Gene Therapies • Genetic Disorders

Clinical data comparison for FDA-approved gene therapies in sickle cell disease. (PubMed, Exp Biol Med (Maywood)) - "In December 2023, the U.S. FDA approved two autologous gene therapies, lovo-cel (bluebird bio) and exa-cel (Vertex/CRISPR Therapeutics), offering potentially transformative outcomes...Mobilization of hematopoietic stem cells (HSCs) with single-agent plerixafor proved challenging in both trials, with most participants requiring multiple mobilization and apheresis cycles...However, differences in trial populations, cell collection logistics, and manufacturing have important implications for real-world applications. Continued long-term follow-up and the establishment of standardized post-treatment registries will be critical to fully assess durability, monitor late effects, and inform patient selection."

Clinical data • FDA event • Journal • Cardiovascular • Gene Therapies • Genetic Disorders • Hematological Disorders • Pediatrics • Sickle Cell Disease • Transplantation

An automated platform for lentiviral transduction for HSC gene therapy promotes fitness of hematopoietic stem cells combined with higher transduction efficiency (ASH 2025) - "Although therapies for HSC gene therapy have been recently approved (Zynteglo™, Lyfgenia™ and Casgevy®), still certain challenges remain associated with high costs, scalability and safety related to leukemic events. Notably, low-density lipoprotein receptor (LDL-R), the cellular receptor that serves for the recognition by the VSV glycoprotein, was accordingly upregulated in cells processed on the CliniMACS Prodigy. These results suggest that the CliniMACS Prodigy promotes higher stemness or better fitness of HSCs while simultaneously allowing for higher transduction efficiencies due to downregulation of immune related pathways and upregulation of cholesterol and sterol binding."

Gene therapy • IO biomarker • Dyslipidemia • Gene Therapies • Immunology • Infectious Disease • CD34 • TLR8